semaglutide alcohol use disorder

GLP-1 Drug Semaglutide Substantially Reduced Heavy Alcohol Consumption and Weight in Patients with Alcohol Use Disorder and O

Your Guilt Cuts Alcohol, But Semaglutide Wins

In a 12-week double-blind trial, semaglutide reduced daily alcohol units by 38%. The same study showed participants also lost an average of 4.7 kg, suggesting the drug can target both drinking and weight simultaneously. 38% reduction in daily alcohol units was observed in the semaglutide arm of the study.

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial — Phot

glp‑1 therapy alcoholism

7 Patients Cut 38% Heavy Drinking With Obesity Treatment

GLP-1 therapy reduces heavy drinking days in obese patients by targeting appetite and reward pathways, cutting weekly binge episodes. In a 2024 pilot, eight weeks of treatment lowered heavy drinking by 38% without adding new medications. In a 2024 pilot trial, just 8 weeks of GLP-1 therapy cut heavy drinking